At the Clinical Trials on Alzheimer's Disease conference on November 17, 2026, Biogen presented mid-stage clinical data showing that a 60-milligram twice-yearly dose of diranersen slowed cognitive decline in early Alzheimer's patients by 38% at two years, up from 26% at 18 months. Developed with Ionis Pharmaceuticals, diranersen silences tau-producing genes and is the first tau-targeting drug to demonstrate clinical efficacy, outperforming amyloid-targeting therapies like Leqembi and Kisunla.
Story comments
Loading comments…